Two new technical posters describe applications performed with proprietary microfluidic technology that combines microscale fluid paths, reaction chambers, and passive valves
Tecan (UK) has announced the free availability of copies of two new technical posters describing applications performed on its innovative LabCD system recently launched at the Drug Discovery Technology 2002 conference (Boston, USA).
Developed in conjunction with five major pharmaceutical companies, the LabCD system benefits from proprietary microfluidic technology that combines microscale fluid paths, reaction chambers, and passive valves.
The result is major reductions in the time and cost of drug development by allowing researchers to obtain critical information much earlier in the drug discovery process.
The first poster describes a seamless fully integrated method for undertaking fluorescence based Cytochrome P450 assays on the LabCD system.
Illustrated with results from a series of Admet applications Tecan's LabCD approach enables greater than ten-fold reductions in reagent usage while limiting non-specific binding issues.
The second poster describes how the Tecan LabCD system in conjunction with Genesis liquid handling workstation and Ultra microplate reader provides a fully automated method using drug displacement of fluorescent dyes specific for three binding sites on serum proteins.
The poster illustrates the simultaneous and rapid determination of the apparent affinities of two compounds for three sites of human serum proteins.
The developed protocol offers push button output of reproducible binding affinities with less time and labour than traditional methods.
